drugset / Trial / NCT02985658

Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer

NCT02985658

Expanded access No longer available University of Washington AbbVie · collab

Summary

This is an expanded access protocol to allow continued maintenance therapy with ABT-888 (veliparib) for three patients with metastatic triple negative breast cancer who are currently receiving the investigational product in association with clinical trial participation. Additionally, the protocol will enroll up to 7 new patients with metastatic BRCA associated or triple negative breast cancer to allow for additional access to veliparib monotherapy, or at the investigator's discretion, veliparib in combination with cisplatin and/or vinorelbine.

Timeline

Start
Primary completion
Completion

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Cisplatin Other / unclassified 75 mg/m2 Intravenous
Subject Veliparib Small molecule 300 mg Oral
Subject Veliparib Small molecule 400 mg Oral
Subject Vinorelbine Small molecule Intravenous